Selection of phage-displayed peptides on live adherent cells in microfluidic channels

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 17, 2011, Pages 6909-6914

  Wang, Jinpeng ^a   Liu, Yanli ^a   Teesalu, Tambet ^b   Sugahara, Kazuki N ^b   Kotamrajua, Venkata Ramana ^b   Adams, Jonathan D ^b   Ferguson, Brian S ^a   Gong, Qiang ^b   Oh, Seung Soo ^a   Csordas, Andrew T ^b   Cho, Minseon ^a   Ruoslahti, Erkki ^b,c   Xiao, Yi ^a   Soh, H Tom ^a  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPILIN 1;

ARTICLE; BINDING AFFINITY; BIOPANNING; CANCER CELL; CELL ADHESION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MICROFLUIDICS; PHAGE DISPLAY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BINDING;

BACTERIOPHAGE T7; CELL LINE, TUMOR; HUMANS; MICROFLUIDIC ANALYTICAL TECHNIQUES; NEUROPILIN-1; PEPTIDE LIBRARY;

EID: 79955558166     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1014753108     Document Type: Article

References (45)

1. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
2. Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323-327. (Pubitemid 18091075)
3. Mori T (2004) Cancer-specific ligands identified from screening of peptide-display libraries. Curr Pharm Design 10:2335-2343.
4. Neri D, et al. (1997) Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 15:1271-1275. (Pubitemid 27465138)
5. MacBeath G (2002) Protein microarrays and proteomics. Nat Genet 32(Suppl):526-532.
6. Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315-1317.
7. Reilly RM, et al. (1995) Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 28:126-142.
8. Aina OH, Sroka TC, Chen ML, Lam KS (2002) Therapeutic cancer targeting peptides. Biopolymers 66:184-199. (Pubitemid 35285218)
9. Nilsson F, Tarli L, Viti F, Neri D (2000) The use of phage display for the development of tumour targeting agents. Adv Drug Deliv Rev 43:165-196.
10. Rozinov MN, Nolan GP (1998) Evolution of peptides that modulate the spectral qualities of bound, small-molecule fluorophores. Chem Biol 5:713-728. (Pubitemid 28560477)
11. Wölcke J, Weinhold E (2001) A DNA-binding peptide from a phage display library. Nucleos Nucleot Nucl 20:1239-1241. (Pubitemid 32821961)
12. Brown KC (2000) New approaches for cell-specific targeting: identification of cellselective peptides from combinatorial libraries. Curr Opin Chem Biol 4:16-21.
13. Hartley O (2002) The use of phage display in the study of receptors and their ligands. J Recept Signal Tr R 22:373-392.
14. Babcock GJ, Mirzabekov T, Wojtowicz W, Sodroski J (2001) Ligand binding characteristics of CXCR4 incorporated into paramagnetic proteoliposomes. J Biol Chem 276:38433-38440.
15. Mirzabekov T, Kontos H, Farzan M, Marasco W, Sodroski J (2000) Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. Nat Biotechnol 18:649-654. (Pubitemid 30415300)
16. Whaley SR, English DS, Hu EL, Barbara PF, Belcher AM (2000) Selection of peptides with semiconductor binding specificity for directed nanocrystal assembly. Nature 405:665-668. (Pubitemid 30428648)
17. Shadidi M, Sioud M (2003) Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J 17:256-258.
18. Zhang J, Spring H, Schwab M (2001) Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett 171:153-164.
19. Pasqualini R, Ruoslahti E (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380:364-366. (Pubitemid 26097120)
20. Rajotte D, et al. (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102:430-437. (Pubitemid 28335203)
21. Barry MA, Dower WJ, Johnston SA (1996) Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med 2:299-305.
22. Robert R, et al. (2006) Identification of human scFvs targeting atherosclerotic lesions: selection by single round in vivo phage display. J Biol Chem 281:40135-40143. (Pubitemid 46041818)
23. Barbas CF, Kang AS, Lerner RA, Benkovic SJ (1991) Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci USA 88:7978-7982. (Pubitemid 21915278)
24. Hust M, Maiss E, Jacobsen HJ, Reinard T (2002) The production of a genus-specific recombinant antibody (scFv) using a recombinant potyvirus protease. J Virol Methods 106:225-233. (Pubitemid 35232607)
25. Mandecki W, Chen YC, Grihalde N (1995) A mathematical model for biopanning (affinity selection) using peptide libraries on filamentous phage. J Theor Biol 176:523-530.
26. Hoffman JA, Laakkonen P, Porkka K, Bernasconi M, Ruoslahti E (2004) Phage Display: A Practical Approach, eds T Clackson and H Lowman (Oxford University Press, Oxford, United Kingdom), pp 171-192.
27. Dennis MS, Lowman HB (2004) Phage Display: A Practical Approach, eds T Clackson and H Lowman (Oxford University Press, Oxford, United Kingdom), pp 61-82.
28. Liu Y, et al. (2009) Controlling the selection stringency of phage display using a microfluidic device. Lab Chip 9:1033-1036.
29. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (2009) C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA 106:16157-16162.
30. Sugahara KN, et al. (2009) Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16:510-520.
31. Starzec A, et al. (2006) Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Life Sci 79:2370-2381. (Pubitemid 44772930)
32. Fong S, Doyle LV, Devlin JJ, Doyle MV (1994) Scanning whole cells with phage-display libraries: identification of peptide ligands that modulate cell function. Drug Develop Res 33:64-70. (Pubitemid 24349993)
33. Myszka DG, Jonsen MD, Graves BJ (1998) Equilibrium analysis of high affinity interactions using BIACORE. Anal Biochem 265:326-330. (Pubitemid 29002079)
34. Mulvaney SP, et al. (2007) Rapid, femtomolar bioassays in complex matrices combining microfluidics and magnetoelectronics. Biosens Bioelectron 23:191-200. (Pubitemid 47391559)
35. Levitan B (1998) Stochastic modeling and optimization of phage display. J Mol Biol 277:893-916.
36. Warrick J, Meyvantsson I, Ju J, Beebe DJ (2007) High-throughput microfluidics: improved sample treatment and washing over standard wells. Lab Chip 7:316-321. (Pubitemid 46348311)
37. Yuan B, Schulz P, Liu R, Sierks MR (2006) Improved affinity selection using phage display technology and off-rate based selection. Electron J Biotechn 9:171-175.
38. Nagel T, Resnick N, Atkinson WJ, Dewey CF, Jr, Gimbrone MA, Jr (1994) Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells. J Clin Invest 94:885-891.
39. Fisher AB, Chien S, Barakat AI, Nerem RM (2001) Endothelial cellular response to altered shear stress. Am J Physiol Lung C 281:L529-533.
40. Silverstein SC, Steinman RM, Cohn ZA (1977) Endocytosis. Annu Rev Biochem 46:669-722.
41. Ng EW, et al. (2001) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123-132.
42. Baldrich E, Restrepo A, O'Sullivan CK (2004) Aptasensor development: elucidation of critical parameters for optimal aptamer performance. Anal Chem 76:7053-7063. (Pubitemid 39600880)
43. Motulsky HJ, Neubig RR (2010) Analyzing binding data. Current Protocols in Neuroscience 52:7.5.1-7.5.65.
44. Cheng Y, PrusoffWH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
45. Stomper PC, Nava ME, Budnick RM, Stewart CC (1997) Specimen mammography-guided fine-needle aspirates of clinically occult benign and malignant lesions. Analysis of cell number and type. Invest Radiol 32:277-281. (Pubitemid 27188328)